• Company
• Prolia's annual sales are expected to be 100 billion won
• by Kim, Jin-Gu Dec 14, 2022 05:56am

• Company
• Baxter ranks first in the 70 billion hemostatic market
• by Nho, Byung Chul Dec 13, 2022 06:07am

• Opinion
• [Reporter’s View] Value of convenience in drug intake
• by Eo, Yun-Ho Dec 13, 2022 06:07am

• Company
• Sales of Actinum series have been sluggish
• by Nho, Byung Chul Dec 13, 2022 06:07am

• Policy
• Reimb of Samil·Kukje's rebamipide eye drops adequate
• by Lee, Tak-Sun Dec 13, 2022 06:07am

• Policy
• Big Pharma's sale of Old Drug has increased
• by Lee, Tak-Sun Dec 13, 2022 06:07am

• Policy
• Will SGLT2 combi benefit expansion eventually not happen?
• by Lee, Tak-Sun Dec 12, 2022 05:48am

• Company
• “Tagrisso shows effect as 1st-line in the real world"
• by Dec 12, 2022 05:48am

• Company
• Nucala retries insurance benefits for the first time in five
• by Eo, Yun-Ho Dec 12, 2022 05:48am

• Company
• Daewoong suspends clinical trials of COVID-19 treatments
• by Kim, Jin-Gu Dec 12, 2022 05:47am